Pharmaceutical compositions suitable for delivery to joints and their use in treating joint pain

Abstract

[Solution] The present disclosure relates to a pharmaceutical composition for treating joint pain.The composition comprises a lipid mixture containing one or more phospholipids and an effective amount of a therapeutic agent or its pharmaceutically acceptable salt, and the total amount of phospholipids in the pharmaceutical composition is about 20mM to about 150mM, optionally 70mM to 110mM.The present disclosure also provides the use of the pharmaceutical composition in treating joint pain by joint injection. [Selected figure] Figure 1

Description

[Technical field]

[0001] The present disclosure relates to pharmaceutical compositions suitable for delivery to joints and methods for treating joint pain that provide a balance between enhancing the therapeutic effect of a therapeutic agent and minimizing side effects. [Background technology]

[0002] Therapies to control joint pain have been developed to reduce joint inflammation and pain by locally delivering therapeutic agents, particularly anti-inflammatory agents, to the joint tissue and have been shown to be effective in temporarily relieving joint pain associated with osteoarthritis and other inflammatory diseases.

[0003] Common methods for the delivery of therapeutic agents to articular tissues are well documented, but their effectiveness is often limited. There are many factors that influence the pharmacokinetics and pharmacodynamics of a therapeutic agent within the joint, including the chemical and physical properties of the selected therapeutic agent, the clearance of particulate vehicles by macrophages, and the properties of the delivery platform.

[0004] In view of the deficiencies outlined above, there is a need for improved therapies for treating joint pain that have a sustained (3-6 months) and more potent therapeutic effect, and preferably also have a reduced side effect profile, particularly related to cartilage damage, chondrocyte damage, or abnormally reduced plasma cortisol levels. The present disclosure addresses these and other needs. Summary of the Invention [Means for solving the problem]

[0005] According to one embodiment of the present disclosure, there is provided a pharmaceutical composition suitable for delivery of a therapeutic agent to a joint, comprising: (a) a lipid mixture comprising one or more phospholipids; (b) an effective amount of a therapeutic agent or a pharma- ceutical acceptable salt thereof, A pharmaceutical composition suitable for delivery of a therapeutic agent to a joint is provided, wherein the total amount of the one or more phospholipids in the pharmaceutical composition is from about 20 μmol to about 150 μmol per milliliter of the pharmaceutical composition.

[0006] Also provided is the following method of treating joint pain: A method of treating joint pain is provided, comprising intra-articularly administering to a subject in need thereof an effective amount of a pharmaceutical composition according to the present disclosure.

[0007] Also provided is the following use of the pharmaceutical composition for the manufacture of a joint injection for the treatment of joint pain: That is, the use of the pharmaceutical composition for the manufacture of a joint injection for the treatment of joint pain, the pharmaceutical composition comprising: (a) a lipid mixture comprising one or more phospholipids; (b) an effective amount of a therapeutic agent or a pharma- ceutically acceptable salt thereof; There is provided a use of the pharmaceutical composition for the manufacture of an injectable joint preparation for treating joint pain, wherein the total amount of the one or more phospholipids per injectable joint is about 20 μmol to about 150 μmol, and the efficacy of the pharmaceutical composition is enhanced as compared to the efficacy of a pharmaceutical composition having a total amount of more than 150 μmol of phospholipids per injectable joint.

[0008] This Summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used alone to determine the scope of the claims, which subject matter should be interpreted with reference to the entire specification, any or all drawings, and appropriate portions of each claim. [Brief description of the drawings]

[0009] [Figure 1] 1 is a line graph showing the release profile of different amounts of phospholipids in a pharmaceutical composition according to the present application.

[0010] [Diagram 2] FIG. 1 is a schematic diagram of the clinical trial design.

[0011] [Diagram 3] FIG. 1 is a schematic diagram showing the clinical trial process.

[0012] [Figure 4A] FIG. 1 shows pain VAS scores associated with subjects administered 6 mg and 12 mg DSP (dexamethasone sodium phosphate) in a pharmaceutical composition of the present disclosure. [Figure 4B] FIG. 1 shows the mean change in pain VAS scores associated with subjects administered 6 mg and 12 mg of DSP in a pharmaceutical composition of the present disclosure.

[0013] [Figure 5A] 1 is a line graph showing the change in mean WOMAC score in subjects administered 6 mg and 12 mg of DSP in a pharmaceutical composition of the present disclosure. [Figure 5B] 1 is a line graph showing the change in mean WOMAC score in subjects administered 6 mg and 12 mg of DSP in a pharmaceutical composition of the present disclosure. [Figure 5C] 1 is a line graph showing the change in mean WOMAC score in subjects administered 6 mg and 12 mg of DSP in a pharmaceutical composition of the present disclosure. [Figure 5D] 1 is a line graph showing the change in mean WOMAC score in subjects administered 6 mg and 12 mg of DSP in a pharmaceutical composition of the present disclosure.

[0014] [Figure 6] 1 is a line graph showing the mean change in WOMAC score by weeks 12, 16, 20, and 24 in subjects administered 6 mg, 12 mg, and 18 mg of DSP in a pharmaceutical composition of the present disclosure.

[0015] [Figure 7]1 is a chart of clinical visual arthritis scores (VAS) in test animals administered a pharmaceutical composition of the present disclosure in an animal model, where the test article was administered on day 16, with the solid arrow indicating the day of treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] definition As used above and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0017] As used herein, the singular forms "a", "one" and "the" do not exclude a plurality unless the context clearly dictates otherwise.

[0018] All numerical values ​​set forth herein should be understood as being "about." As used herein, "about" refers to ±10% of the specific numerical value.

[0019] As used herein, the term "articular injection" includes local injection at or near the site of joint pain, intra-articular injection, or peri-articular injection.

[0020] As used herein, an "effective amount" refers to a dose of a pharmaceutical composition sufficient to reduce the symptoms and signs of diseases that cause joint pain, such as joint pain, inflammation, joint stiffness and swelling, and to reduce side effects associated with the injection of a therapeutic agent, where reduction can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or any amount therebetween.

[0021] The terms "treat", "treated" or "treatment" as used herein include preventing (e.g., prophylactically), slowing, arresting or reversing progressive structural tissue damage that causes joint pain. Also, throughout this application, treatment refers to methods of reducing, alleviating, arresting or delaying joint pain, or complete amelioration of joint pain, which can be measured by known techniques. These include, but are not limited to, laboratory tests, imaging or analysis of serum or joint aspirates (e.g., rheumatoid factor, erythrocyte sedimentation rate), to name a few. For example, the methods of the present disclosure are contemplated to treat a subject to reduce joint pain by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to a pre-treatment subject or a control subject. Treatment includes a single joint injection or multiple joint injections at desired intervals.

[0022] The term "subject" can refer to a vertebrate having joint pain or deemed in need of treatment for joint pain. Subjects include warm-blooded animals, such as mammals, such as primates, and more preferably humans. Non-human primates are also subjects. The term subject includes domesticated animals, such as cats and dogs, farm animals (e.g., cows, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mice, rabbits, rats, gerbils, guinea pigs, etc.). Thus, veterinary applications and medical formulations are also contemplated by the present disclosure.

[0023] The term "arthralgia" refers to a joint disorder or disease involving inflammation and pain in one or more joints. As used herein, the term "arthralgia" includes various types and subtypes of arthritis of various etiologies and causes, known or unknown, including, but not limited to, rheumatoid arthritis, osteoarthritis, infectious arthritis, psoriatic arthritis, gouty arthritis, lupus-associated arthritis, or painful local tissues affected by bursitis, tenosynovitis, epicondylitis, synovitis, or other disorders.

[0024] "Pharmaceutically acceptable salts" of the therapeutic agents of the present disclosure include salts of acidic therapeutic agents formed with bases, i.e., base addition salts such as alkali and alkaline earth metal salts, e.g., sodium, lithium, potassium, calcium, magnesium, and tetraammonium salts, such as ammonium, trimethylammonium, diethylammonium, and tris(hydroxymethyl)methylammonium salts. Similarly, acid addition salts of mineral acids, organic carboxylic acids, organic sulfonic acids, e.g., hydrochloric acid, methanesulfonic acid, maleic acid, and the like, can also be provided for basic therapeutic agents.

[0025] Pharmaceutical Compositions In one embodiment, the present disclosure provides a pharmaceutical composition comprising a lipid mixture comprising one or more phospholipids and an effective amount of a therapeutic agent or a pharma- ceutically acceptable salt thereof, wherein the total amount of the one or more phospholipids in the pharmaceutical composition is from about 20 μmol to about 150 μmol per mL of the pharmaceutical composition.

[0026] In one embodiment, the pharmaceutical composition of the present disclosure provides release of a therapeutic agent lasting for 3 months, 4 months, 5 months, 6 months or more, or for 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 22 weeks, or 23 weeks.

[0027] In another embodiment, the pharmaceutical composition of the present disclosure has enhanced efficacy compared to that of a pharmaceutical composition having a total amount of phospholipids of about 150 μmol or more per mL of the pharmaceutical composition. In yet another embodiment, the pharmaceutical composition of the present disclosure has a sustained therapeutic effect of a therapeutic agent and a reduced side effect of the therapeutic agent.

[0028] In one embodiment, the total amount of phospholipids per mL of the pharmaceutical composition is 50 μmol to 140 μmol. In another embodiment, the total amount of phospholipids per mL of the pharmaceutical composition is 45 μmol to 135 μmol. In yet another embodiment, the total amount of phospholipids per mL of the pharmaceutical composition is 50 μmol to 120 μmol. In yet another embodiment, the total amount of phospholipids per mL of the pharmaceutical composition is 60 μmol to 110 μmol.

[0029] In one embodiment, the pharmaceutical composition of the present disclosure further comprises at least one pharma- ceutically acceptable excipient, diluent, vehicle, carrier, medium for the active ingredient, preservative, cryoprotectant, or a combination thereof.

[0030] In one embodiment, the pharmaceutical composition of the present disclosure is prepared by mixing one or more phospholipids, with or without cholesterol, with one or more buffering agents to form liposomes, lyophilizing the liposomes together with one or more bulking agents to form a lipid mixture cake, and reconstituting the lipid mixture cake with a solution containing the therapeutic agent to form an aqueous suspension.

[0031] In another embodiment, the pharmaceutical composition of the present disclosure is prepared by mixing one or more phospholipids in a solvent, with or without cholesterol, then removing the solvent to form a lipid mixture in powder or film form, and reconstituting the lipid mixture powder or film with a solution containing a therapeutic agent to form an aqueous suspension. In another embodiment, the pharmaceutical composition of the present disclosure is prepared by mixing one or more phospholipids in a solvent, with or without cholesterol, then injecting the dissolved lipid solution into an aqueous solution to form liposomes. The liposomes are then downsized by filtering through a track-etched polycarbonate membrane. The solvent is removed by diafiltration against a buffer solution using a semi-automated tangential flow filtration (TFF) system. The diafiltered liposome solution is then lyophilized to a powder form, and the lipid mixture powder or film is reconstituted with a solution containing a therapeutic agent to form an aqueous suspension.

[0032] In some embodiments, the pharmaceutical compositions of the present disclosure contain about 10% to about 50% lipid-associated therapeutic agent, or about 50% to about 90% unassociated therapeutic agent. The term "unassociated form" refers to a therapeutic agent molecule that can be separated from the phospholipid / cholesterol fraction of the pharmaceutical composition via gel filtration to provide an immediate release component. In other embodiments, the weight ratio of the combination of phospholipid and cholesterol to the therapeutic agent is about 5 to 80 to 1, and in yet other embodiments, the weight ratio of the combination of phospholipid and cholesterol to the therapeutic agent is about 5 to 40 to 1. The weight ratio of the combination of phospholipid and cholesterol to the therapeutic agent can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 to 1.

[0033] Depending on the embodiment, the concentration of the therapeutic agent in the pharmaceutical compositions of the present disclosure can be about 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, 35 mM or more, and optionally can range from about 10 mM to about 40 mM, about 15 mM to about 40 mM, about 20 mM to about 40 mM, about 15 mM to about 35 mM, about 15 mM to about 30 mM, about 15 mM to about 25 mM, about 20 mM to about 25 mM.

[0034] In some embodiments, the total volume of the pharmaceutical composition for each administration ranges from about 0.5 mL to about 1.5 mL, and can optionally be about 1.0 mL.

[0035] lipid mixture The lipid mixture of the pharmaceutical composition provided herein refers to a phospholipid or a mixture of phospholipids. The lipid mixture may be in the form of, but is not limited to, a film, a cake, a granule or a powder before being added to the pharmaceutical composition.

[0036] In one embodiment, the phospholipid or mixture of phospholipids, with or without cholesterol, are pre-formed into liposomes before being further processed as a lipid mixture.

[0037] In another embodiment, the phospholipid or mixture of phospholipids, with or without cholesterol, are not pre-formed into liposomes before being further processed as a lipid mixture.

[0038] Liposomes are nano-sized and consist of a lipid monolayer or bilayer surrounding an aqueous drug-carrying interior. Non-limiting examples of liposomes include small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), multivesicular liposomes (MVLs) and multilamellar vesicles (MLVs).

[0039] Lipid mixtures can be prepared from various lipids that can form or incorporate into monolayer or bilayer structures.The lipids used in the present disclosure include, but are not limited to, one or more of the following lipids: phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), and phosphatidylinositol (PI). In some embodiments, the lipid mixture comprises egg phosphatidylcholine (EPC, egg phosphatidylglycerol (EPG), egg phosphatidylethanolamine (EPE), egg phosphatidylserine (EPS), egg phosphatidic acid (EPA), egg phosphatidylinositol (EPI), soy phosphatidylcholine (SPC), soy phosphatidylglycerol (SPG), soy phosphatidylethanolamine (SPE), soy phosphatidylserine (SPS), soy phosphatidic acid (SPA), soy phosphatidylinositol (SPI), or combinations thereof.In another embodiment, the lipid mixture is dipalmitoyl phosphatidylcholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidylglycerol (DOPG), dimyristoyl phosphatidylglycerol (DMPG), hexadecylphosphocholine (HEPC), hydrogenated soybean. Phosphatidylcholine (HSPC), distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidylethanolamine (DOPE), palmitoylstearoylphosphatidylcholine (PSPC), palmitoylstearoylphosphatidylglycerol (PSPG), monooleoylphosphatidylethanolamine (MOPE), l-palmitoyl-2-oleoyl-sn-glycerol Cero-3-phosphatidylcholine (POPC), polyethylene glycol distearoylphosphatidylethanolamine (PEG-DSPE), dipalmitoylphosphatidylserine (DPPS), 1,2-dioleoyl-sn-glycero-3-phosphatidylserine (DOPS), dimyristoylphosphatidylserine (DMPS), distearoylphosphatidylserine (DSPS), dipalmitoylphosphatidic acid (DPPA), l,2-dioleoyl -sn-glycero-3-phosphatidic acid (DOPA), dimyristoyl phosphatidic acid (DMPA), distearoyl phosphatidic acid (DSPA), dipalmitoyl phosphatidylinositol (DPPI), l,2-dioleoyl-sn-glycero-3-phosphatidylinositol (DOPI), dimyristoyl phosphatidylinositol (DMPI), distearoyl phosphatidylinositol (DSPI), or combinations thereof.

[0040] In some embodiments, the lipid mixture comprises a first phospholipid and a second phospholipid. In some embodiments, the first phospholipid is selected from the group consisting of EPC, EPE, SPC, SPE, DPPC, DOPC, DMPC, HEPC, HSPC, DSPC, DOPE, PSPC, MOPE, POPC, and the second phospholipid is selected from the group consisting of PG, PS, PA, PI, EPG, EPS, EPA, EPI, SPG, SPE, SPS, SPA, SPI, DPPG, DOPG, DMPG, DSPG, PSPG, DPPS, DOPS, DMPS, DSPS, DPPA, DOPA, DMPA, DSPA, DPPI, DOPI, DMPI, DSPI, and a hydrophilic polymer having a long chain of highly hydrated flexible neutral polymer attached to the phospholipid molecule. Examples of hydrophilic polymers include polyethylene glycol (PEG) having a molecular weight of about 2000 to about 5000 daltons, methoxy PEG (mPEG), ganglioside GMi, polysialic acid, polylactic acid (also called polylactide), polyglycolic acid (also called polyglycolide), polylactic acid polyglycolic acid, polyvinyl alcohol, polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxyethyloxazoline, polyhydroxypropyloxazoline, polyaspartamide, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyvinyl methyl ether, polyhydroxyethyl acrylate, derivatized celluloses such as hydroxymethyl cellulose and hydroxyethyl cellulose, and synthetic polymers, but are not limited to these.

[0041] In one embodiment, the lipid mixture further comprises a sterol. The sterols used in the present disclosure are not particularly limited, but examples thereof include cholesterol, phytosterols (such as sitosterol, stigmasterol, fucosterol, spinasterol, brassicasterol, etc.), ergosterol, cholestanone, cholestenone, coprostenol, cholesteryl-2'-hydroxyethyl ether, and cholesteryl-4'-hydroxybutyl ether. The sterol component of the lipid mixture, if present, can be any of the sterols conventionally used in the field of preparing liposomes, lipid vesicles, or lipid particles. In another embodiment, the lipid mixture comprises about 10% to about 33% cholesterol, about 15 mol% to less than about 30 mol% cholesterol, about 18 mol% to about 28 mol% cholesterol, or about 20 mol% to about 25 mol% cholesterol.

[0042] In an exemplary embodiment, the lipid mixture comprises a first phospholipid, a second phospholipid, and a sterol in the following ratio, by mole percentage: 29.5%-90%: 3%-37.5%: 10%-33%.

[0043] In a further embodiment, the first phospholipid is DOPC, POPC, SPC, or EPC and the second phospholipid is PEG-DSPE or DOPG.

[0044] In one embodiment, the lipid mixture does not include fatty acids or cationic lipids (ie, lipids that carry a net positive charge at physiological pH).

[0045] In some embodiments, the lipid mixture may further comprise lipid conjugates of peptides or antibodies that function as targeting moieties to enable the liposomes to specifically bind to target cells bearing the target molecule. Non-limiting examples of target molecules include B cell surface antigens such as TNF-α and CD20. Other antigens may also be used, such as CD19, HER-3, GD2, Gp75, CS1 protein, mesothelin, cMyc, CD22, CD4, CD44, CD45, CD28, CD3, CD123, CD138, CD52, CD56, CD74, CD30, Gp75, CD38, CD33, GD2, VEGF, or TGF.

[0046] The liposomes prepared in this disclosure can be produced by conventional techniques used to form vesicles. These techniques include ether injection (Deamer et al., Acad. Sci. (1978) 308: 250), detergent method (Brunner et al., Biochim. Biophys. Acta (1976) 455: 322), freeze-thaw method (Pick et al., Arch. Biochim. Biophys. (1981) 212: 186), reverse phase evaporation (Szoka et al., Biochim. Biophys. Acta. (1980) 601: 559 71), sonication (Huang et al., Biochemistry (1969) 8: 344), ethanol injection (Kremer et al., Biochemistry (1977) 16: 3932), extrusion (Hope et al., Biochim. Biophys. Acta (1985) 812: 55 65), the French press method (Barenholz et al., FEBS Lett. (1979) 99: 210), and the method described by Szoka, F., Jr. et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980). All of the above methods are basic techniques for the formation of vesicles, and these methods are incorporated herein by reference. After sterilization, the preformed liposomes are aseptically placed into a container and lyophilized to form a powder or cake. In embodiments where the lipid mixture comprises preformed liposomes, the liposomes are obtained by solvent injection and then lyophilized to form the lipid mixture. The lipid mixture comprises one or more bulking agents. In one embodiment, the lipid mixture further comprises one or more buffering agents.

[0047] Examples of bulking agents include, but are not limited to, polyols, sugar alcohols such as mannitol, glycerol, sorbitol, dextrose, sucrose, etc., and amino acids such as trehalose, histidine, glycine, etc. One preferred bulking agent is mannitol.

[0048] Buffering agents include, but are not limited to, sodium phosphate monobasic dihydrate and sodium phosphate dibasic anhydrous.

[0049] In embodiments where the lipid mixture includes lipids that have not been preformed into liposomes, the lipid mixture can be prepared by dissolving the lipids in a suitable organic solvent, such as ethanol, methanol, t-butyl alcohol, ether, and chloroform, and drying by heating, vacuum evaporation, nitrogen evaporation, lyophilization, or other conventional methods of solvent removal.

[0050] A specific example of the preparation of a lipid mixture consistent with the present disclosure is set forth below.

[0051] Therapeutic Agents The therapeutic agent can be a steroid, a nonsteroidal anti-inflammatory drug (NS AID) such as indomethacin, a disease-modifying antirheumatic drug (DMARD), or a combination of two or more of these, as well as one or more of these in combination with other ingredients or compounds not specifically described herein. DMARDs include small molecule drugs such as methotrexate, leflunomide, sulfasalazine, cyclophosphamide, azathioprine, cyclosporine A, d-penicillamine, and antimalarials (such as hydroxychloroquine). DMARDs also include biological agents, such as tumor necrosis factor a (TNF-a) antagonists (e.g., etanercept, available under the trade name Enbrel from Wyeth, Collegeville, USA, and adalimumab, available under the trade name Humira from Abbott Laboratories, Abbott Park, Illinois, USA), interleukin-1 receptor antagonists, interleukin-6 receptor antagonists, anti-CD20 monoclonal antibodies, CTLA-4-Ig, and RGD peptides.

[0052] In one exemplary embodiment, the therapeutic agent is a substantially water-soluble steroid, such as dexamethasone sodium phosphate (DSP), in the form of a solution. In another exemplary embodiment, the therapeutic agent is a substantially water-soluble NSAID, such as an acceptable salt of indomethacin. In yet another exemplary embodiment, the therapeutic agent is a substantially water-soluble DMARD, such as an acceptable salt of methotrexate, or a TNF-a antagonist. In yet another exemplary embodiment, the therapeutic agent is not covalently bound to a phospholipid or fatty acid, such as palmitate.

[0053] The therapeutic agent according to the present disclosure can be mixed into either ddFUO or a suitable buffer to suspend the lipid mixture and provide a solution containing the therapeutic agent to obtain a pharmaceutical composition of the present disclosure, and in some embodiments, the therapeutic agent is not covalently attached to a lipid, such as a phospholipid, or a fatty acid, such as palmitic acid.

[0054] The therapeutic agent or drug may be combined with pharma- ceutically acceptable excipients and other ingredients suitable for pharmaceutical formulations, including formulations for humans and animals, and formulations for research, experimental, and related uses. In some embodiments, a citrate buffer is used, preferably sodium citrate. In other embodiments, a chelating agent is used, preferably EDTA.

[0055] The therapeutic agent in the pharmaceutical compositions described herein includes a therapeutic agent or a pharma- ceutically acceptable salt thereof suitable for joint injection. In one embodiment, the therapeutic agent is suitable for intra-articular (IA) injection. Intra-articular injection includes the following steps: (1) identifying and marking a suitable injection site in the joint to be treated, (2) sterilizing the injection site using sterile technique and optionally administering a local anesthetic, (3) inserting the needle into the joint cavity, and (4) injecting the agent into the joint cavity. In some embodiments, the needle insertion may be performed under ultrasound guidance. A small amount of synovial fluid is aspirated to ensure that the tip of the needle is within the joint cavity.

[0056] Steroids useful in the present disclosure include any naturally occurring steroid hormone, synthetic steroid and derivatives thereof. Examples of steroids include, but are not limited to, cortisone, hydrocortisone, hydrocortisone acetate, tixocortol pivalate, fluocinolone, prednisolone, methylprednisolone, prednisone, triamcinolone acetonide, triamcinolone, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, halcinonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate (DSP), fluocortolone, hydrocortisone-17-butyrate, hydrocortisone-17-valerate, alclometasone dipropionate, Betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, fluprednidene acetate, difluprednate, loteprednol, fluorometholone, medrysone rimexolone, beclomethasone, cloprednol, cortivazol, deoxycortone, difluorocortolone, fluclorolone, fluorocortisone, flumethasone, flunisolide, fluorocortolone, flurandrenolone, meprednisone, methylprednisolone, paramethasone, or mixtures thereof. In an exemplary embodiment, the steroid is a water-soluble steroid. Water-soluble steroids include naturally occurring steroid hormones, synthetic steroids, and their derivatives. Water-soluble steroids include, but are not limited to, cortisone, hydrocortisone, prednisolone, methylprednisolone, prednisone, DSP, hydrocortisone-17-valerate, fluorocortisone, fludrocortisone, methylprednisolone, paramethasone, and prerenone. In one example, to reconstitute the lipid mixture in the form of a cake to obtain the pharmaceutical composition of the present disclosure, a DSP solution of about 2 mg to about 100 mg / mL, about 4 mg to about 80 mg / mL, about 5 mg to about 60 mg / mL, about 6 mg to about 40 mg / mL, about 8 mg to about 20 mg / mL, or about 10 mg to about 16 mg / mL can be used as a solution containing the therapeutic agent as described above.In another exemplary embodiment, the steroid is selected from Group B and Group C steroids according to the Coopman classification (see S. Coopman et al., "Identification of cross reaction patterns in allergic contact dermatitis from topical corticosteroids," Br J Dermatol. 1989 Jul;l2l(l):27-34).

[0057] Pharmaceutically acceptable salts of therapeutic agents include non-toxic salts formed from non-toxic inorganic or organic bases, such as inorganic bases, such as hydroxides of alkali or alkaline earth metals, for example potassium, sodium, lithium, calcium, or magnesium, or from organic bases, such as amines.

[0058] Pharmaceutically acceptable salts of therapeutic agents also include non-toxic salts formed from non-toxic inorganic or organic acids, such as, for example, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, succinic acid, citric acid, lactic acid, maleic acid, fumaric acid, palmitic acid, cholic acid, pamoic acid, mucic acid, D-glutamic acid, glutaric acid, glycolic acid, phthalic acid, tartaric acid, lauric acid, stearic acid, salicylic acid, sorbic acid, benzoic acid, and the like.

[0059] The therapeutic agent can be administered in an effective amount by joint injection to reduce symptoms or signs of arthritis. In one embodiment, the therapeutic agent refers to a steroid, particularly an intra-articular corticosteroid (e.g., but not limited to, a corticosteroid such as hydrocortisone acetate, methylprednisolone acetate, dexamethasone sodium acetate, betamethasone acetate, prednisolone, triamcinolone acetonide, or triamcinolone hexacetonide), which is administered in a dose of about 0.1 mg to about 300 mg, or about 0.1 mg to about 100 mg, or about 10 ... It can be administered in a dose range of about 100 mg, about 0.1 mg to about 20 mg, about 0.1 mg to about 18 mg, about 1 mg to about 300 mg, about 1 mg to about 100 mg, about 1 mg to about 20 mg, about 1 mg to about 18 mg, about 4 mg to about 300 mg, about 4 mg to about 100 mg, about 4 mg to about 20 mg, about 4 mg to about 18 mg, about 6 mg to about 18 mg, about 6 mg to about 16 mg, about 8 mg to about 16 mg, about 6 mg to about 12 mg, or about 6 mg to about 16 mg.

[0060] The effective dosage of the therapeutic agent in humans may be higher than the recommended or standard dosages known in the art, see, for example, The Orthopaedic Journal of Sports Medicine, 3(5), 2325967115581163 (DOI: 10.1177 / 2325967115581163), which is incorporated herein by reference. For example, the recommended effective and tolerable dosage of the therapeutic agent triamcinolone hexacetonide is 20 mg, but the dosage of the therapeutic agent in the compositions and methods of the present invention may be at least 20 mg or more.

[0061] It should be noted that the dosage of therapeutic agent administered will also depend on the severity of the disease being treated, the particular formulation, and other clinical factors such as the weight and overall condition of the subject and the severity of side effects.

[0062] Use of the pharmaceutical composition The pharmaceutical composition may be administered once or multiple times for a period appropriate for the disease to be treated. The pharmaceutical composition may be administered at suitable intervals, for example, once every week, every two weeks, every six weeks, every month, every two months, every three or more months, every six or more months, or until the symptoms and signs of the disease (i.e., joint pain) are remitted, depending on the convenience.

[0063] In one group of embodiments, the multiple dose treatment with at least two joint injections is administered with a dosing interval selected from the group consisting of 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, and 23 weeks.

[0064] In some embodiments, the pharmaceutical composition is administered in an amount ranging from about 0.5 mL to about 1.5 mL, about 0.6 mL to about 1.2 mL, about 0.8 mL to about 1.2 mL, or about 1.0 mL per joint injection.

[0065] How to Treat Joint Pain One aspect of the present disclosure is directed to providing a method of treating joint pain in a subject, comprising administering to a subject in need of treatment for joint pain an effective amount of a pharmaceutical composition described herein, whereby side effects induced by the therapeutic agent are reduced as compared to side effects in the subject following administration of an immediate release or standard therapeutic agent formulation, and / or the efficacy and release rate of the therapeutic agent of the pharmaceutical composition is increased as compared to the efficacy and release rate of a pharmaceutical composition comprising about 150 μmol or more of phospholipid per mL of the pharmaceutical composition. In one embodiment, the subject is a patient suffering from osteoarthritis, rheumatoid arthritis, acute gouty arthritis, psoriatic arthritis, reactive arthritis, or arthritis due to Ehlers-Danlos syndrome, hemochromatosis, hepatitis, Lyme disease, Sjogren's disease, Hashimoto's thyroiditis, celiac disease, non-celiac gluten sensitivity, inflammatory bowel disease, Henoch-Schonlein purpura, type D hyperimmunoglobulinemia with relapsing fever, sarcoidosis, Whipple's disease, TNF receptor-associated periodic syndrome, granulomatosis with polyangiitis, familial Mediterranean fever, or systemic lupus erythematosus.

[0066] Here, efficacy refers to the ability of the therapeutic agent to induce a favorable clinical response to the disease. Efficacy also refers to the reduction of clinical signs such as joint pain, tenderness, transient morning stiffness, crepitus during joint movement, which lead to instability and physical disability. In one embodiment, the efficacy of the therapeutic agent is determined by WOMAC OA index, VAS score, etc. In some embodiments, the sustained steady release of the therapeutic agent from the pharmaceutical compositions described herein does not induce side effects such as damage or destruction of articular cartilage, e.g., chondrocyte apoptosis, loss of proteoglycan, articular cartilage cysts, deterioration of articular cartilage, or joint destruction. The reduction in side effects in the subjects described herein can be in the range of 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to subjects injected with the therapeutic agent without the pharmaceutical compositions described herein, e.g., without the lipid mixture. Such effects are unexpected since exposure to therapeutic agents, such as triamcinolone acetate (TCA), is well known to cause damage or destruction of articular cartilage.

[0067] The pharmaceutical compositions provided herein may be used in combination with any of a variety of additional chemical entities, including, but not limited to, painkillers (e.g., bupivacaine, ropivacaine, lidocaine) or hyaluronic acid formulations (e.g., Synvisc One). In some embodiments, the claimed pharmaceutical composition and the additional chemical entity are formulated into a single therapeutic composition, and the claimed pharmaceutical composition and the additional chemical entity are administered simultaneously. In other aspects, the claimed pharmaceutical composition and the additional chemical entity are separate from one another, e.g., each is formulated into a separate therapeutic composition, and the claimed pharmaceutical composition and the additional chemical entity are administered in a single dose or multiple doses, by the same or different routes, at the same time or at different times during a treatment regimen.

[0068] The following examples further illustrate the present disclosure. These examples are intended merely to illustrate the specific aspects of the disclosure and are not to be construed as limiting the invention.

[0069] Example 1. Preparation of lipid mixture Lipids including DOPC, DOPG and cholesterol were mixed in a molar ratio of 67.5:7.5:25 and dissolved in 99.9% ethanol at approximately 40° C. in a flask to form a lipid solution. A benchtop ultrasonic bath was used to dissolve the lipids.

[0070] The dissolved lipid solution was added to a 1.0 mM sodium phosphate solution at 100 mL / min using a peristaltic pump to form a proliposomal suspension. The proliposomal suspension was then passed 6–10 times through a polycarbonate membrane with a pore size of 0.2 μm. This resulted in a liposome mixture with an average vesicle diameter of the liposomes of approximately 120 nm–140 nm (measured with a Malvern ZetaSizer Nano ZS-90, Malvern Instruments Ltd, Worcestershire, UK).

[0071] The liposome mixture was filtered through a Millipore Pellicon 2 Mini Ultrafiltration Module Biomax-100C (0.1m 2 The solution was dialyzed and concentrated using a tangential flow filtration system equipped with a 0.2 μm sterilizing filter (manufactured by Millipore Corporation, Billerica, Massachusetts, USA) and then sterilized using a 0.2 μm sterilizing filter.

[0072] The lipid concentration of the filtered liposome mixture was quantified by phosphorus measurement, and the filtered liposome mixture was mixed with mannitol at a concentration of 2% and then sterilized again using a 0.2 μm sterile filter. The sterilized liposome mixture was freeze-dried to obtain a lipid mixture in the form of a cake.

[0073] Example 2. Preparation of pharmaceutical compositions A pharmaceutical composition according to the present disclosure was prepared by mixing the lipid mixture described in Example 1 with a DSP solution. The DSP solution contained 13.2 mg / mL dexamethasone sodium phosphate (DSP) (C 22 H 28 The DSP solution contained FNa2O8P (molecular weight 516.41 g / L) and 4 mg / mL sodium citrate. The pharmaceutical composition prepared from this was used below as a DSP pharmaceutical composition, and the contents of DSP and phospholipid per mL were about 12.0 mg / mL and 90 μmol, respectively.

[0074] Example 3. Controlled release of pharmaceutical compositions An in vitro release study was conducted in a Phase II dose-finding clinical setting. The pharmaceutical composition of Example 2 was injected into human synthetic synovial fluid (hsSF) at different DSP doses and the amount of DSP released was measured at each time point.

[0075] Human synthetic synovial fluid (hsSF) The composition of the human synthetic synovial fluid is shown in Table 1. Briefly, bovine serum albumin (BSA) was dissolved in 0.9% saline to a concentration of 30 mg / mL. 1% hyaluronic acid (HA, Mw = 1.35 × 10 6 The mixture was gently stirred at room temperature for 2 hours to ensure complete dissolution of the hyaluronic acid. The pH of the solution was 7.3. Human synthetic synovial fluid was supplemented with 0.2% sodium azide to inhibit bacterial growth. [Table 1]

[0076] In Vitro Release of DSP Pharmaceutical Compositions The release of DSP from liposomes of the DSP pharmaceutical composition was measured by detecting the change in encapsulation efficiency at different time intervals. Briefly, various amounts of the DSP pharmaceutical composition were suspended in synthetic synovial fluid at a given temperature (37°C) and stirred at 150 rpm with a stir bar (Table 2). At appropriate time intervals, the suspension was collected and the free DSP was collected by eluting the suspension through an SPE column, and the encapsulation efficiency was measured as follows: [Table 2]

[0077] Encapsulation Efficiency After separating free DSP from liposomes using an SPE cartridge, the absorbance of the collected sample was measured for the encapsulation efficiency. The SPE column was wetted with 1 mL of methanol and then with 1 mL of distilled water before use. The column was then equilibrated with 1 mL of saline before loading with the collected suspension. After loading with the suspension, the SPE column was washed with 3 mL of distilled water, and free DSP was eluted with 2 mL of elution buffer (containing 2M NHOAc / MeOH / ACN=2 / 9 / 9 (v / v)). The eluted fractions containing free DSP were monitored at 240 nm using a UV-vis spectrophotometer. The encapsulation efficiency (%) was calculated as [1-(Ifree / 12)]×100, where 12 is the theoretical value of DSP in the sample solution (mg / mL) and Ifree is the free DSP concentration.

[0078] Data was obtained that the release of DSP can be controlled by adjusting the total amount of phospholipid (Table 3, Figure 1). Without wishing to be bound by any theory, it is believed that when the total amount of lipids in the pharmaceutical composition is high and the dose of DSP is relatively high (composition No. 5 in Table 3), a small amount of DSP is released slowly into the joint environment, while when the total amount of lipids is low and the dose of DSP is low, it is believed that a sufficient and sustainable level of free DSP cannot be generated over time. Taking into account the results of the Phase II dose-finding clinical trial described below, it is believed that a pharmaceutical composition containing an appropriate amount of phospholipid is desirable for controlling the release of a therapeutic agent used to treat joint pain. Based on the fact that the volume of synovial fluid is generally in the range of 1 mL to 70 mL, a substantial phospholipid concentration of 20 μmol to 150 μmol per mL of pharmaceutical composition can be achieved to achieve a desired effective lipid concentration of about 90 μmol per 7 mL of synovial fluid. [Table 3] Example 4. Randomized, open-label study of the efficacy and safety of dexamethasone sodium phosphate (DSP) pharmaceutical composition in patients with knee osteoarthritis

[0079] method A 12-week randomized, open-label, parallel, single-dose phase I / II clinical trial was conducted at three study sites in Taipei, Taiwan. A schematic diagram of the study design is shown in Figure 2. The study was approved by the Institutional Review Board at each study site prior to recruitment of subjects. The study was conducted in accordance with the principles set forth in the US CFR 21 part 312.20, the Declaration of Helsinki, and the ICH (International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use) Clinical Trials Guideline. The study protocol is registered with ClinicalTrial.gov (NCT02803307). Written informed consent was obtained from all patients to participate in the study.

[0080] Patients aged 20 years or older and with a diagnosis of osteoarthritis (OA) of the knee for at least 6 months prior to the screening visit were recruited for this study. The diagnosis of OA was based on clinical and radiological criteria in the American Rheumatism Association classification criteria for idiopathic knee osteoarthritis (Arthritis Rheum. 1986;29:1039-49). In addition, subjects were required to have knee severity of at least grade 2 according to the Kellgren-Lawrence classification (Br J Ind Med. 1952;9:197-207), a baseline visual analog scale (VAS) pain score of 4 or higher, and to be able to understand the study protocol and consent to participate. Patients were excluded from the study if they had used systemic corticosteroids within 30 days prior to baseline, had used NSAIDs, analgesics, or rehabilitation therapy within 7 days prior to baseline, had a medical history of Reiter's syndrome, systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, inflammatory myositis, mixed connective tissue disease, relapsing rheumatoid arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Behçet's disease, arthritis associated with inflammatory bowel disease, sarcoidosis, vasculitis, cryoglobulinemia, or amyloidosis, or had clinical signs and symptoms of acute infection or infection-related inflammation in the other knee before administration.

[0081] A total of 46 patients with knee osteoarthritis were screened, and 40 patients who met the inclusion criteria were randomly assigned to two groups. The screening visit took place within 14 days before the start of the study. Only one knee was selected as the study knee, and the study drug was administered and subsequently evaluated. If potential acute inflammation or infection occurred in the other knee, administration of the study drug was discontinued. The subjects were randomly divided 1:1 into two groups and administered a single dose of the DSP pharmaceutical composition prepared by the method described in Example 2 at the following two dose levels: (1) 6 mg of DSP containing approximately 45 μmol of phospholipid (Group A), and (2) 12 mg of DSP containing approximately 90 μmol of phospholipid (Group B). The DSP pharmaceutical composition used in this study was prepared by the method described in each of the above examples and was designed to provide both short-acting (immediate) and long-acting forms of DSP after reconstitution. Each subject was evaluated over a 12-week period following a single intra-articular injection.

[0082] The primary objective of this study is to evaluate the safety and tolerability of the DSP pharmaceutical composition at two different dose levels. Safety was evaluated based on adverse events (AEs), serious adverse events (SAEs), vital signs, and changes in physical examination, electrocardiogram, and laboratory tests. Secondary objectives of this study are to evaluate the efficacy of the DSP pharmaceutical composition by measuring changes in subject and physician reported pain scores (VAS), Western Ontario and McMaster Universities osteoarthritis Index (WOMAC) arthritis index scores, and Investigator Global Assessment of Response to Therapy (IGART) scores of the study subjects' knees. VAS and WOMAC assessments were performed at weeks 0, 1, 4, 8, and 12, respectively, and IGART assessments were performed at weeks 1, 4, 8, and 12. Knee pain scores were assessed using a VAS scale (scale ranges from 0 (no pain / discomfort) to 10 (worst pain / discomfort ever)). The WOMAC index includes three subscales: pain (5 items), stiffness (2 items), and physical function (17 items), with scores ranging from 0 to 4. Patients' responses to the administration of the study drug were determined by the investigator on each regular visit except for baseline by selecting one of five grades (no effect, poor, fair, good, excellent) on the IGART assessment.

[0083] statistical analysis The sample size of this study was not determined by pre-specified statistical power assumptions. A total of 40 patients with knee osteoarthritis were planned to be enrolled in this study. All statistical evaluations were two-sided and evaluated at a significance level of 0.05. Missing data (including those due to early discontinuation) were not entered. For continuous endpoints (safety assessment of plasma cortisol, WOMAC index, and VAS score), descriptive statistics such as number of observations, mean, median, standard deviation, minimum, and maximum were presented in the raw data along with the change from baseline. In addition, continuous variables were analyzed using the Wilcoxon rank sum test to compare differences between treatment groups, and the Wilcoxon signed-rank test was used to compare changes from baseline. For categorical endpoints (number of patients achieving ≥30% or ≥50% reduction from baseline in IGART, WOMAC, and VAS), numbers and percentages were used. To compare differences between groups, chi-square tests were performed, and Fisher's exact test was applied when data were scarce. All statistical analyses were performed using SAS® software (SAS System for Windows 7, version 9.3). In this study, the safety population was used for safety analysis, and the intent-to-treat (ITT) and per-protocol (PP) populations were used for efficacy analysis. The safety population was defined as all subjects who received any dose of the DSP pharmaceutical composition. The ITT population was defined as subjects who received at least one total dose of the DSP pharmaceutical composition and underwent at least one post-baseline efficacy assessment. The PP population was defined as all subjects in the ITT population who did not have any major protocol deviations or violations. All 40 subjects were included in the safety and ITT populations. Thirteen subjects, including 6 in group A and 7 in group B, were included in the PP population. The main conclusions are based on the PP population.

[0084] result A total of 46 subjects were screened in this study, of which 6 were screening failures. Forty subjects were enrolled in the study, of which 39 met the eligibility criteria. In addition, one additional subject was enrolled who had been diagnosed with knee osteoarthritis within 6 months prior to screening. The subjects were randomly divided into groups A and B, each of which had 20 subjects, and received 6 mg of DSP containing 45 μmol of phospholipid and 12 mg of DSP containing 90 μmol of phospholipid per intra-articular injection, respectively. The treatment outline of the subjects is shown in Figure 3, and the demographic information of the subjects is shown in Table 4. [Table 4]

[0085] All 40 subjects were of East Asian descent. The mean age was 67.4 years, and 8 (20%) were men. Subjects were classified as grade 2 (n = 12), grade 3 (n = 20), or grade 4 (n = 8) according to the KL classification.

[0086] No serious adverse events or adverse events leading to withdrawal or death occurred in this study. Because long-term use of corticosteroids can lead to elevated blood glucose levels and even diabetes, changes in HbA1c were measured. No statistically significant differences were observed between groups A and B in the mean change in HbA1c from baseline (week 0) to week 12.

[0087] A transient decrease in cortisol is a well-known physiological response in patients receiving IA injections of corticosteroids. Mean cortisol levels showed a decrease from baseline 1 week after injection, but remained within the normal range, and no subjects reported signs or symptoms of adrenal insufficiency.

[0088] In the PP population, mean subject- and physician-relevant pain scores (VAS scores) showed sustained reductions from baseline at each scheduled visit through the end of the study at week 12 in both groups A and B (Figure 4A and Figure 4B). The mean changes in subject VAS from baseline to weeks 1, 4, 8, and 12 in group A were -2.45, -1.90, -1.80, and -1.95, respectively. In group B, the mean changes in subject VAS from baseline to weeks 1, 4, 8, and 12 were -3.90, -3.23, -3.33, and -3.14, respectively. Statistical significance (p<0.05) was only achieved for the mean changes from baseline to each scheduled visit in group B. The mean changes in physician-related VAS from baseline to weeks 1, 4, 8, and 12 in group A were -2.95, -4.33, -3.22, and -4.90, respectively. In group B, the mean changes in physician-related VAS from baseline to weeks 1, 4, 8, and 12 were -3.41, -3.03, -3.80, and -4.33, respectively. All mean changes from baseline were statistically significant except for the mean change from baseline to week 8 in group A (-3.22 ± 1.78, p = 0.0625). A similar trend was observed in the ITT population.

[0089] The reduction in the WOMAC pain, stiffness, and physical function subscale scores from baseline to each regular visit was more pronounced in Group B than in Group A (Figures 5A-5D). The mean WOMAC total score at baseline (week 0) was 37.83 + 19.90 in Group A and 43.29 + 15.16 (mean + SD) in Group B in the PP population. The mean changes in WOMAC total score from baseline to weeks 1, 4, 8, and 12 were -12.17, -8.33, -9.00, and -10.83, respectively, in Group A, and -19.00, -22.29, -20.71, and -20.14, respectively, in Group B. A similar trend was observed in the ITT population.

[0090] In both the ITT and PP populations, there was no statistical significance between group A and group B in IGART assessments at weeks 1, 4, 8, and 12. In the PP population (n=13), 33-67% of patients in group A were rated as good responders and 43-100% of patients in group B were rated as good responders by the investigator from weeks 1 to 12. In the ITT population (n=20), 50-65% of patients in group A were rated as good responders and 45-60% of patients in group B were rated as good responders by the investigator from weeks 1 to 12.

[0091] In this Phase I / II clinical trial, intra-articular injections of the DSP pharmaceutical composition were well tolerated by all subjects with knee osteoarthritis (OA). Other adverse events (AEs) reported in the study were not related to treatment, and most of these were low in severity. No serious adverse events (SAEs), major adverse events (injection-related local reactions), or adverse events leading to either withdrawal or death occurred.

[0092] The DSP pharmaceutical composition did not show microscopic findings such as loss of proteoglycan in rabbits and beagle dogs. In addition, while cartilage damage has been reported as a result of multiple intra-articular administration of steroids such as free dexamethasone and triamcinolone, the DSP pharmaceutical composition did not induce cartilage damage or cartilage toxicity in animal experiments, even after single or multiple intra-articular administration.

[0093] Dexamethasone demonstrated pain relief and arthritis improvement comparable to the long-acting corticosteroid triamcinolone, suggesting that a DSP pharmaceutical composition with a sustained release profile may be able to enhance the therapeutic effect of dexamethasone for a much longer period of time than other drugs in its class.

[0094] This Phase I / II clinical trial is the first to administer a DSP pharmaceutical composition containing 20μmol / 150μmol or a total amount of 80μmol / 110μmol of phospholipids per mL via intra-articular injection to subjects with knee osteoarthritis. This trial demonstrated that administration of 6mg-12mg of the DSP pharmaceutical composition for 12 weeks or more provided a longer duration of therapeutic effect compared to other corticosteroids. After a single dose of the DSP pharmaceutical composition, pain relief as measured by the pain VAS score and symptom relief as measured by the WOMAC OA index tended to persist for 12 weeks. Example 5. Comparative analysis of the efficacy of DSP pharmaceutical compositions in patients with knee osteoarthritis

[0095] A multicenter, double-blind, placebo-controlled Phase II clinical trial to explore the safety and therapeutic efficacy of the DSP pharmaceutical composition at two different dose levels in patients with knee osteoarthritis was completed in August 2018. In this clinical trial, 75 patients with a mean age of 63.9 years, moderate knee osteoarthritis, and a pain VAS score of 5 to 9 were randomly assigned to three different study groups, each of which received a single intra-articular administration of (a) a pharmaceutical composition containing 12 mg of DSP and 90 μmol of phospholipid (hereinafter referred to as TLC599 12 mg), (b) a pharmaceutical composition containing 18 mg of DSP and 135 μmol of phospholipid (hereinafter referred to as TLC599 18 mg), or (c) a placebo control (saline) (hereinafter simply referred to as placebo).

[0096] The primary endpoint was assessment of the mean change from baseline in WOMAC pain score through week 12. Secondary endpoints included other analyses such as change from baseline in WOMAC pain score, WOMAC physical function score, and VAS pain score at various time points through week 24, along with other analyses such as the proportion of clinically durable responders. Safety and efficacy assessments were performed at day 3, week 1, and every 4 weeks through week 24.

[0097] Using the WOMAC pain assessment index, TLC599 12 mg demonstrated statistically significant improvements in pain relief compared to placebo from day 3 through week 12, meeting the primary endpoint. Additionally, TLC599 12 mg demonstrated sustained and statistically significant improvements in pain relief compared to placebo from day 3 through weeks 16, 20, and 24, reflecting persistence of pain control for at least 24 weeks, as shown in Figure 6 and Table 5. Additionally, TLC599 12 mg demonstrated statistically significant improvements in pain relief compared to placebo at weeks 12, 16, 20, and 24.

[0098] [Table 5]

[0099] Similar results were observed using WOMAC physical function score as the efficacy measure: patients receiving TLC599 12 mg showed greater improvements in WOMAC physical function score compared to placebo from day 3 through weeks 12, 16, 20, and 24 (p<0.05).

[0100] Furthermore, similar results were observed when VAS pain scores were used as the efficacy measure. TLC599 12 mg demonstrated statistically significant improvements in pain relief compared to placebo from day 3 through weeks 12, 16, 20, and 24, again reflecting sustained pain control for at least 6 months. TLC599 12 mg also demonstrated statistically significant improvements in pain relief compared to placebo at weeks 12, 16, 20, and 24.

[0101] Transient cortisol reductions are a well-known physiological response in patients receiving intra-articular injections of corticosteroids. Thus, the cortisol reductions observed in this study were expected pharmacodynamic responses to closely monitored intra-articular injections of corticosteroids. Laboratory abnormalities in blood cortisol concentrations were reported to be mild in intensity, with two exceptions (one moderate cortisolism and one severe glucocorticoid deficiency). None of these cortisol laboratory abnormalities were accompanied by signs or symptoms that could be attributed to hypocortisolism, and all resolved without treatment or sequelae. Most of these events occurred at day 3, and most of them had resolved by the next week-1 visit.

[0102] The total amount of free dexamethasone contained in 12 mg of TLC599 (approximately 40%) is slightly greater than the typical immediate release DSP dose (4 mg) used for intra-articular injection.

[0103] Treatment-emergent adverse events (TEAEs) observed in this study were expected for the study population. TLC599 was generally safe and well tolerated. Furthermore, TLC599 12 mg was associated with lower rates of overall TEAEs, drug-related AEs, and cortisol-related AEs than TLC599 18 mg.

[0104] Fasting glucose levels were monitored at every visit in the study. One patient in the 12 mg TLC599 group experienced a TEAE of elevated glucose (2 separate events, 1 mild, 1 moderate), and one patient in the 18 mg TLC599 group experienced an AE of decreased fasting glucose (mild). However, the elevated glucose levels (both events) were deemed unrelated to study treatment.

[0105] Of note, these patients did not show abnormalities in HbA1c levels during the trial, and therefore any increases in blood glucose levels were likely transient and mild. Example 6. Evaluation of the effect of lipid content in a DSP pharmaceutical composition in an animal model of osteoarthritis

[0106] To assess the effect of varying lipid content and drug-lipid interactions on in vivo performance as a pharmaceutical composition suitable for delivery to joints, DSPs with high and low lipid contents were prepared and assessed for potential efficacy under the conditions indicated below.

[0107] To investigate the effect of lipid content of DSP pharmaceutical composition on the therapeutic activity of DSP, rats with collagen type II induced arthritis (CIA) model were used. A total of 30 Lewis rats were induced with collagen type II emulsified with Freund's incomplete adjuvant (FIA) on day 1 and boosted again by tail intradermal injection on day 8. Clinical visual arthritis score, which indicates the severity of arthritis, was graded using an arthritis index ranging from 0 to 4 (see Table 6). The scores of both hind paws were summed to give each rat a total score, so that the maximum possible score for an individual rat is 8. On day 17, when the disease was successfully induced with a total clinical visual arthritis score of 8, the rats were administered the test article to both paws. DSP pharmaceutical compositions with different total lipid amounts were prepared in a similar manner to that described in Example 2, except that the resulting lipid contents were different as shown in Table 7 below. As controls, lipid-free saline and 12 mg / mL dexamethasone phosphate (DP) injection (unprepared drug) were used. [Table 6] [Table 7]

[0108] Results were obtained showing a correlation between lipid content in pharmaceutical compositions suitable for delivery to the joint and anti-arthritic effect based on clinical visual score assessment (Figure 7).

[0109] In vivo efficacy studies reported that the TLC599 formulations, regardless of lipid content (67 μmol phospholipid or more per mL of DSP pharmaceutical composition), provided at least a 2.5-fold increase in the duration of efficacy over the unformulated drug. However, in conjunction with Example 3 above, it is speculated that a longer duration of anti-arthritic activity can be obtained if the lipid content range of the DSP pharmaceutical composition according to this example (67 μmol phospholipid or more per mL of DSP pharmaceutical composition, e.g., about 70 μmol to about 120 μmol) is used. Thus, the pharmaceutical composition according to the present disclosure can actually provide sustained release of DSP at the lipid content indicated, particularly in the dosage ranges indicated, allowing a balance to be achieved between improved therapeutic efficacy and minimized side effects of the therapeutic agent.

Claims

1. A pharmaceutical composition for delivering a therapeutic agent to a joint, comprising: (a) a lipid mixture comprising 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG) and cholesterol in a molar percentage of 67.5:7.5:25; and (b) an effective amount of a therapeutic agent or a pharma- ceutical acceptable salt thereof; A pharmaceutical composition, wherein the total amount of phospholipids in the lipid mixture ranges from 90 μmol to 150 μmol per mL of the pharmaceutical composition.

2. The pharmaceutical composition of claim 1 , wherein the therapeutic agent is a steroid.

3. 2. The pharmaceutical composition of claim 1, wherein the therapeutic agent is an intra-articular corticosteroid.

4. 2. The pharmaceutical composition of claim 1, wherein the therapeutic agent is dexamethasone sodium phosphate, dexamethasone, betamethasone, betamethasone sodium phosphate, betamethasone acetate, betamethasone dipropionate, betamethasone valerate, mometasone furoate, triamcinolone acetonide, triamcinolone hexacetonide, triamcinolone diacetate, methylprednisolone sodium succinate, methylprednisolone acetate, prednisolone tebutate, hydrocortisone acetate, alclometasone dipropionate, halcinonide, fluocortolone, fluocinolone acetonide, or a combination thereof.

5. 3. The pharmaceutical composition of claim 2, wherein the steroid is dexamethasone sodium phosphate.

6. 6. The pharmaceutical composition of claim 5, wherein the dexamethasone sodium phosphate is present in an amount ranging from 6 mg to 18 mg per mL of pharmaceutical composition.

7. 6. The pharmaceutical composition of claim 5, wherein the dexamethasone sodium phosphate is present in an amount ranging from 6 mg to 12 mg per mL of pharmaceutical composition.

8. 6. The pharmaceutical composition of claim 5, wherein the dexamethasone sodium phosphate is present in an amount of 12 mg per mL of the pharmaceutical composition.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the total amount of phospholipids in the lipid mixture is in the range of 90 μmol to 140 μmol per mL of pharmaceutical composition.

10. The pharmaceutical composition according to any one of claims 1 to 8, wherein the total amount of phospholipids in the lipid mixture is in the range of 90 μmol to 135 μmol per ml of pharmaceutical composition.

11. The pharmaceutical composition according to any one of claims 1 to 8, wherein the total amount of phospholipids in the lipid mixture is in the range of 90 μmol to 120 μmol per ml of pharmaceutical composition.

12. The pharmaceutical composition according to any one of claims 1 to 8, wherein the total amount of phospholipids in the lipid mixture is in the range of 90 μmol to 110 μmol per ml of pharmaceutical composition.

13. The pharmaceutical composition according to any one of claims 1 to 8, wherein the total amount of phospholipids in the lipid mixture is from 90 μmol to 100 μmol per ml of pharmaceutical composition.

14. 1. Use of a pharmaceutical composition for the manufacture of an injectable joint preparation for treating joint pain, the pharmaceutical composition comprising: (a) a lipid mixture comprising 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG) and cholesterol in a molar percentage of 67.5:7.5:25; and (b) an effective amount of a therapeutic agent or a pharma- ceutical acceptable salt thereof; Use of a pharmaceutical composition for the manufacture of an injectable joint preparation for treating joint pain, wherein the total amount of phospholipids in said lipid mixture per joint injection ranges from 90 μmol to 150 μmol, and the efficacy of the pharmaceutical composition is enhanced compared to the efficacy of a pharmaceutical composition having a total amount of phospholipids of more than 150 μmol per joint injection.

15. 15. The use according to claim 14, wherein the therapeutic agent is a steroid.

16. 15. The use according to claim 14, wherein the therapeutic agent is an intra-articular corticosteroid.

17. 15. The use of claim 14, wherein the therapeutic agent is dexamethasone sodium phosphate, dexamethasone, betamethasone, betamethasone sodium phosphate, betamethasone acetate, betamethasone dipropionate, betamethasone valerate, mometasone furoate, triamcinolone acetonide, triamcinolone hexacetonide, triamcinolone diacetate, methylprednisolone sodium succinate, methylprednisolone acetate, prednisolone tebutate, hydrocortisone acetate, alclometasone dipropionate, halcinonide, fluocortolone, fluocinolone acetonide, or a combination thereof.

18. 16. The use according to claim 15, wherein the steroid is dexamethasone sodium phosphate.

19. 19. The use according to claim 18, wherein the dexamethasone sodium phosphate is present in an amount ranging from 6 mg to 18 mg per joint injection.

20. 19. The use according to claim 18, wherein the dexamethasone sodium phosphate is present in an amount of 12 mg per joint injection.

21. The use according to any one of claims 14 to 20, wherein the total amount of phospholipids in the lipid mixture ranges from 90 μmol to 140 μmol per joint injection.

22. The use according to any one of claims 14 to 20, wherein the total amount of phospholipids in the lipid mixture ranges from 90 μmol to 135 μmol per joint injection.

23. The use according to any one of claims 14 to 20, wherein the total amount of phospholipids in the lipid mixture ranges from 90 μmol to 120 μmol per joint injection.

24. The use according to any one of claims 14 to 20, wherein the total amount of phospholipids in the lipid mixture ranges from 90 μmol to 110 μmol per joint injection.

25. The use according to any one of claims 14 to 20, wherein the total amount of phospholipids in the lipid mixture is 90 μmol per joint injection.

26. The use according to any one of claims 14 to 20, wherein said efficacy refers to the reduction of at least one clinical sign selected from joint pain, tenderness, transient morning stiffness, crepitus on joint movement.

27. The use according to any one of claims 14 to 20, wherein the pharmaceutical composition is administered once a week, once every two weeks, once every six weeks, once a month, once every two months, once every three or more months, once every six or more months until joint pain disappears.

28. 15. The use according to claim 14, wherein the joint pain is due to arthritis.

29. 29. The use of claim 28, wherein the arthritis is psoriatic arthritis, reactive arthritis, or arthritis due to Ehlers-Danlos syndrome, hemochromatosis, hepatitis, Lyme disease, Sjogren's disease, Hashimoto's thyroiditis, celiac disease, non-celiac gluten sensitivity, inflammatory bowel disease, Henoch-Schonlein purpura, type D hyperimmunoglobulinemia with relapsing fever, sarcoidosis, Whipple's disease, TNF receptor-associated periodic syndrome, granulomatosis with polyangiitis, familial Mediterranean fever, or systemic lupus erythematosus.

Images